➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Harvard Business School
Dow
McKinsey
Express Scripts

Last Updated: July 27, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CYRAMZA

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for CYRAMZA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01285037 ↗ A Study of LY2801653 in Advanced Cancer Recruiting Eli Lilly and Company Phase 1 2009-11-01 Part A- The purpose of this study is to determine a safe dose of LY2801653 to be given to participants with advanced cancer and to determine any side effects that may be associated with LY2801653 in this participant population. Efficacy measures will be used to assess the activity of LY2801653. Part B- The dose determined in Part A will be used along with efficacy measures to assess the activity of LY2801653 in participants with adenocarcinoma of the colon or rectum, head and neck squamous cell carcinoma (HNSCC), uveal melanoma with liver metastasis, and cholangiocarcinoma. Part C - the objective of Part C is to determine a recommended Phase 2 dose of LY2801653 that may be safely given to participants with HNSCC when taken with standard doses of cetuximab Part D - the objective of Part D is to determine a recommended Phase 2 dose of LY2801653 that may be safely given to participants with cholangiocarcinoma when taken with a standard dose of cisplatin. Part E - the objective of Part E is to determine a recommended Phase 2 dose of LY2801653 that may be safely given to participants with cholangiocarcinoma when taken with gemcitabine plus cisplatin. Part F - the objective of Part F is to determine a recommended Phase 2 dose of LY2801653 that may be safely given to participants with gastric cancer when taken with ramucirumab.
NCT02079636 ↗ A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) Recruiting Merck Sharp & Dohme Corp. Phase 1 2014-03-01 The main purpose of this study is to evaluate the safety and tolerability of abemaciclib in combination with another anti-cancer drug in participants with NSCLC that is advanced or has spread to other parts of the body (stage IV). The study will also investigate how the body processes the combination treatment and how the study drug affects the body. The study will also collect disease-related symptoms and participant-reported pain related to NSCLC.
NCT02079636 ↗ A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) Recruiting Eli Lilly and Company Phase 1 2014-03-01 The main purpose of this study is to evaluate the safety and tolerability of abemaciclib in combination with another anti-cancer drug in participants with NSCLC that is advanced or has spread to other parts of the body (stage IV). The study will also investigate how the body processes the combination treatment and how the study drug affects the body. The study will also collect disease-related symptoms and participant-reported pain related to NSCLC.
NCT02213289 ↗ PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression Recruiting Amgen Phase 1/Phase 2 2015-01-01 The purpose of this study is to determine if doctors can use the results of special tests of subjects tumor tissue, that will look for specific abnormalities in the tumor, to choose a specific drug that is targeted to work against that abnormality (called molecular profiling) and to see what effects (good and/or bad) that targeted drug has on subjects cancer when it is given with standard chemotherapy.
NCT02213289 ↗ PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression Recruiting University of Chicago Phase 1/Phase 2 2015-01-01 The purpose of this study is to determine if doctors can use the results of special tests of subjects tumor tissue, that will look for specific abnormalities in the tumor, to choose a specific drug that is targeted to work against that abnormality (called molecular profiling) and to see what effects (good and/or bad) that targeted drug has on subjects cancer when it is given with standard chemotherapy.
NCT02314117 ↗ A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer Active, not recruiting Eli Lilly and Company Phase 3 2015-01-01 The main purpose of this study is to evaluate the effectiveness of ramucirumab, which is a targeted antibody, in combination with capecitabine and cisplatin compared to capecitabine and cisplatin alone in participants with stomach cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for CYRAMZA

Condition Name

Condition Name for CYRAMZA
Intervention Trials
Gastric Adenocarcinoma 6
Gastroesophageal Junction Adenocarcinoma 6
Non-small Cell Lung Cancer 5
Stage IVA Lung Cancer AJCC v8 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for CYRAMZA
Intervention Trials
Adenocarcinoma 18
Esophageal Neoplasms 13
Carcinoma, Non-Small-Cell Lung 10
Lung Neoplasms 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for CYRAMZA

Trials by Country

Trials by Country for CYRAMZA
Location Trials
United States 162
Germany 8
Mexico 8
Spain 8
Italy 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for CYRAMZA
Location Trials
California 11
Tennessee 8
Texas 8
Illinois 7
Missouri 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for CYRAMZA

Clinical Trial Phase

Clinical Trial Phase for CYRAMZA
Clinical Trial Phase Trials
Phase 3 4
Phase 2/Phase 3 1
Phase 2 23
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for CYRAMZA
Clinical Trial Phase Trials
Not yet recruiting 22
Recruiting 16
Active, not recruiting 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CYRAMZA

Sponsor Name

Sponsor Name for CYRAMZA
Sponsor Trials
Eli Lilly and Company 20
National Cancer Institute (NCI) 9
Merck Sharp & Dohme Corp. 4
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for CYRAMZA
Sponsor Trials
Industry 36
Other 29
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Merck
Harvard Business School
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.